Core Viewpoint - Credit Suisse has raised its sales forecasts for Innovent Biologics (01801) for this year, next year, and 2027 by 2.7%, 0.8%, and 2.8% respectively, while also increasing net profit forecasts by 90.4%, 25.3%, and 25.3% for the same years, with a target price adjustment from HKD 108.4 to HKD 111.4, maintaining an "outperform" rating [1] Group 1 - Innovent Biologics reported a strong mid-year performance, with sales increasing by 50.6% year-on-year and achieving a net profit of RMB 834 million, exceeding expectations [1] - The approval of GLP-1 dual agonists and the upcoming launch of IL-23 are expected to further drive profitability growth for Innovent Biologics [1] - The highly anticipated PD-1/IL-2 drug IBI363 is ready for a global MRCT trial targeting I/O recurrent squamous non-small cell lung cancer, while the CLDN18.2 ADC is undergoing a second MRCT trial for pancreatic cancer [1]
里昂：升信达生物(01801)目标价至111.4港元 中绩胜预期